Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 18/20 | 0.44 |
| ▸ | OXGR1 | Q96P68 | 2/20 | 0.40 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGAV | P06756 | 2/20 | 0.36 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2488314 | 1.00 | SUCNR1 (0.44) | SUCNR1OXGR1BDKRB1ITGB3ITGAV | |
| SCHEMBL861448 | 0.82 | ACP1 (0.32) | SUCNR1 | |
| SCHEMBL861449 | 0.82 | ACP1 (0.32) | SUCNR1 | |
| SCHEMBL2488316 | 0.78 | USP9X (0.33) | SUCNR1OXGR1 | |
| SCHEMBL861782 | 0.75 | SUCNR1 (0.44) | SUCNR1OXGR1ITGB3ITGAVITGB5 | |
| SCHEMBL861147 | 0.75 | SUCNR1 (0.40) | SUCNR1OXGR1ITGB3ITGAVITGB5 | |
| SCHEMBL861146 | 0.75 | SUCNR1 (0.40) | SUCNR1OXGR1ITGB3ITGAVITGB5 | |
| SCHEMBL860604 | 0.73 | SUCNR1 (0.38) | SUCNR1OXGR1ITGB3ITGAVITGB5 | |
| SCHEMBL861442 | 0.72 | ITGB3 (0.54) | SUCNR1OXGR1ITGB3ITGAVITGB5 | |
| SCHEMBL5245682 | 0.67 | SUCNR1 (0.53) | SUCNR1OXGR1BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425010-B1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | LU TIANBO | 2007-09-20 | — | — | US | disclosed |
| US-7241789-B2 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICAL, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050250771-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | disclosed |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-09-22 | — | — | US | disclosed |
| US-6855722-B2 | Substituted indoles and their use as integrin antagonists | DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | ITGA5, ADGRE5, ITGAV | SUCNR1 1024/4885OXGR1 1246/4885BDKRB1 49/4885 |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | SUCNR1 949/4885OXGR1 1510/4885BDKRB1 65/4885 |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGAL, ITGA5 | SUCNR1 559/4885OXGR1 1358/4885BDKRB1 85/4885 |
| US-20050250771-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | SUCNR1 943/4885OXGR1 1471/4885BDKRB1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.